Despite low PRLR expression (0.09x total PRLR as MCF7), HepG2 had tumor growth delay (p < 0.001 compared to vehicle, p < 0.005 compared to Co-PBD) when treated with ABBV-176 at 0.2 mg/kg Q7D × 3 as shown in the survival chart (Fig. 2F). The gene discussed is PRLR; the disease is neoplasm.